Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”), a pharma company focused on the development of a novel treatment for gastroesophageal reflux disease (“GERD”), today announces that two abstracts from the company’s phase II study, LEED, on its leading drug candidate linaprazan glurate, developed for the treatment of moderate to severe erosive GERD (“eGERD”), are being presented at the leading gastro conference United European Gastroenterology (“UEG”) which is held in Copenhagen 14 – 17 October 2023.

Read Press Release here